Role of the 5-HT2C receptor in atypical antipsychotics: Hero or villain?

Current Medicinal Chemistry - Central Nervous System Agents

Volumn 5, Issue 1, 2005, Pages 63-66

  Wood, Martyn ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

6 CHLORO 5 METHYL 1 [[2 [(2 METHYL 3 PYRIDYL)OXY] 5 PYRIDYL]CARBAMOYL]INDOLINE; ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; ALPHA ADRENERGIC RECEPTOR; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; ANXIOLYTIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; EPLIVANSERIN; G PROTEIN COUPLED RECEPTOR; HALOPERIDOL; HISTAMINE H1 RECEPTOR; MIANSERIN; MIRTAZAPINE; NEUROTRANSMITTER RECEPTOR; PHOSPHOLIPASE A2; PHOSPHOLIPASE C; QUETIAPINE; RITANSERIN; SEROTONIN 2 RECEPTOR; SEROTONIN 2A ANTAGONIST; SEROTONIN 2A RECEPTOR; SEROTONIN 2B RECEPTOR; SEROTONIN 2C ANTAGONIST; SEROTONIN 2C RECEPTOR; SEROTONIN UPTAKE INHIBITOR; UNINDEXED DRUG;

AKATHISIA; BINDING AFFINITY; CARDIOVASCULAR DISEASE; CATALEPSY; DIABETES MELLITUS; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG TOLERABILITY; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; LIGAND BINDING; MOTOR DYSFUNCTION; NONHUMAN; OBESITY; ORTHOSTATIC HYPOTENSION; PARKINSONISM; PATIENT COMPLIANCE; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR AFFINITY; RECEPTOR BLOCKING; RECEPTOR OCCUPANCY; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; SIGNAL TRANSDUCTION; TARDIVE DYSKINESIA; WEIGHT GAIN;

EID: 15344351415     PISSN: 15680150     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568015053202732     Document Type: Review

References (54)

1. Meltzer, H.Y. Br. J. Psychiat., 1966, 168(suppl. 29), 23-31.
2. Meltzer, H.Y., Matsubara, S. Lee, M.A. J. Pharmacol. Exp. Ther., 1989, 251, 238-246
3. Altar, C.A., Waslet, A.M., Neale, R.F., Stone, G.A. Brain Res. Bull., 1986, 76(4), 517-525
4. Buckley, N.A.; Sanders, P. Drug Safety, 2000, 23 (3), 215-228
5. Allison, D.B., Mentore J.L., Heo, M., Chandler, L.P., Cappalleri, J.C., Infante, M.C., Weiden, P.J. Am. J. Psychiat., 1999, 156, 1686-1696.
6. Kroeze, W.K., Hufeisen, S.J., Popadak, B.A., Renock, S.M., Steinberg, S., Ernsberger, P., Jayathilake, K., Meltzer, H.Y., Roth, B.L. Neuropsychopharmacol., 2003, 28 (3), 519-526.
7. Roth, B.L., Willins, D.L., Kristiansen, K., Kroeze, W.K. Pharamacol. Ther., 1998, 79, 231-257.
8. Hoyer, D., Hannon, J.P., Martin, G.R. Pharmacol. Biochem. & Behav., 2002, 71, 533-554.
9. Leysen, J.E.; Niemegers, C.J.E.; Van Nueton, J.M.; Laduron, P.M. Mol. Pharmacol., 1982, 21, 301-14.
10. Blurton, P.A., Wood, M.D. J. Neurochem., 1986, 46, 1392-1398.
11. Baxter, G., Kennett, G., Blaney, F., Blackburn, T. Trends In Pharmacol. Sci., 1995, 16, 105-110.
12. Duxon, M.S., Flanigan, T.P., Reavley, A.C., Baxter, G.S., Blackburn, T.P., Fone, K.C. Neurosci., 1997, 76(2), 323-329.
13. Mengod, G., Vilaro, M.T., Raurich, A., Lopez-Gimenez, J.F., Palacios, J.M. Histochem J. 1996, 28(11), 747-758.
14. Wood, M.D., Heidbreder, C., Reavill, C., Ahsby, C.R., Middlemiss, D.N. Drug Dev. Res., 2001, 54, 88-94.
15. Roth, B.L., Ciaranello, R.D., Meltzer, H.Y. J. Pharmacol. Exp. Ther., 1992, 260, 1361-1365.
16. Duinkerke, S.J., Botter, P.A., Jansen, A.A., van Dongen, P.A., van Haaften, A.J., Boom, A.J., van Laarhoven, J.H.M., Busard, H.L.S.M. Br. J. Psychiat., 1993, 163, 451-455.
17. Weisel, F.A., Nordstrom, A.L., Farde, L., Eriksson, B. Psychopharmacol., 1994, 114, 31-38.
18. Liegois, J-F., Ichikawa, J., Meltzer, H.Y. Brain Res., 2002, 947, 157-165.
19. Kuroki, T., Meltzer, H.Y., Ichikawa, J. J. Pharmacol. Exp. Ther., 1999, 288, 774-781.
20. Di Matteo, V., Cacchio, M., Di Giulio, C., Esposito, E. Pharmacol. Biocehm. & Behav., 2002, 71, 727-734,
21. Kennett, G.A., Wood, M.D., Bright, F., Trail, B., Riley, G., Holland, V., Avenell, K.Y., Stean, T., Upton, N., Bromidge, S., Forbes, I.T., Brown, A.M., Middlesmiss, D.N., Blackburn, T.P. Neuropharmacol., 1997, 36, 609-620.
22. Millan, M.J., Dekeyne, A., Gobert, A. Neuropharmacol., 1998, 37, 953-955.
23. Ashby, C.R. Jr, Wang, R.Y. Synapse, 1996, 24, 349-394.
24. Wood, M.D., Reavili, C.A., Trail, B., Wilson, A., Stean, T., Kennett, G.A., Lightowler, S., Blackburn, T.P., Thomas, D., Gager, T.L., Riley, G., Holland, V., Bromidge, S.M., Forbes, I.T., Middlemiss, D.N. Neuropharmacol., 2001, 4l, 186-199.
25. Cornea Hebert, V., Riad, M., Wu, C., Singh, S.K., Descarries, L. J. Comp. Neurol., 1999, 409, 187-209.
26. Eberle-Wang, K., Mikeladze, Z., Uryu, K., Chesselet, M.F. J. Comp. Neurol., 1997, 384, 233-247.
27. Olijslagers, J.E., Werkman, T.R., McCreary, A.C., Siarey, R., Kruse, C.G., Wadman, W.J. Neuropharmacol., 2004, 46, 504-510.
28. Bonaccorso, S., Meltzer, H.Y., Li, Z., Dai, J., Alboszta, A.R., Ichikawa, J. Neuropsychopharmacol., 2002, 27, 430-441.
29. Grinshpoon, A., Valevski, A., Moskowitz, M., Weizman, A. Eur. Psychiat., 2000, 15, 388-390.
30. Meltzer, H.Y., Arvanitis, L., Bauer, D., Rein, W. Am. J. Psychiat., 2004, 161, 975-984.
31. Tarazi, F.I., Zhang, K., Baidessarini, R.J. J. Pharmacol. Exp. Ther., 2001, 297, 711-717.
32. Reavill, C.A., Kettle, A., Holland, V., Riley, G., Blackburn T.P. Br. J. Pharmacol., 1999, 126, 572-574.
33. Lucas, G., Bonhomme, N., De Deurwaerdere, P., Le Moal, M., Spampinato, U. Psychopharmacol., 1997, 131, 57-63.
34. Meltzer, H.Y., Li, Z., Kaneda, Y., Ichikawa, J. Prog. Neuropsychopharmacol. & Biol. Psychiat., 2003, 27, 1159-1172.
35. Moller, H-J. CNS Drugs, 2003, 17, 793-823.
36. Karow, A., Lambert M. Curr. Opin. Psychiat., 2003, 16, 713-718.
37. Zoccali, R., Muscatello, M.R., Cedro, C., Neri, P., La Torre, D., Spina, E., Di Rosa, A.E., Meduri, M. Int. Clin. Psychopharmacol., 2004, 19(2), 71-76.
38. Tohen, M., Vieta, E., Calabrese, J., Ketter, T.A., Sachs, G., Bowden, C., Mitchell, P.B., Centorrino, F., Risser, R., Baker, R.W., Evans, A.R., Beymer, K., Dube, S., Tollefson, G.D., Breier, A. Arch. Gen. Psychiat., 2003, 60, 1079-1088.
39. Wood, M.D. Curr. Drug Targets - CNS & Neurology. Disorders, 2003, 2, 383-387.
40. Wood, M.D., Thomas, D.R., Watson, J.M. Expert Opin. Investig. Drugs, 2002, 11, 457-467.
41. Allison, D.B., Mentore, J.L., Heo, M., Chandler, L.P., Infante, M.C., Weiden, P.J. Am. J. Psychiat., 1999, 156, 1686-1696.
42. Allison, D.B., Casey, D.E. J. Clin. Psychiat., 2001, 62 (Suppl. 7), 22-31.
43. Lean, M.E.J., Pajonk, F-K. Diabetes Care, 2003, 26, 1597-1605.
44. Casey, D.E., Zorn, S.H. J. Clin. Psychiat., 2001, 62 (Suppl. 7), 4-10.
45. Dourish, C.T., Obes. Res., 1995, 3, S449-62.
46. Orthen-Gambill, N. Pharmacol. Biochem. Behav., 1988, 31, 81-86.
47. Schreiber, R., De Vry, J. Prog. Neuro-Psychopharmacol. & Biol. Psychiat., 2002, 26, 441-449.
48. Tecott, L.H., Sun, L.M. Akana, S.F., Strack, A.M., Lowenstein, D.H., Dallman, M.F., Julius, D. Nature, 1995, 374, 542-546.
49. Giorgetti, M., Tecott, L.H. Eur. J. Pharmacol., 2004, 488, 1-9
50. Reynolds, G.P., Zhang, Z., Zhang, X.B. Am. J. Psychiat., 2003, 160, 677-679.
51. Pooley, E.C., Fairburn, C.G., Cooper, Z., Sodhi, S., Cowen, P.J., Harrison, P.J. Am. J. Med. Gen., 2004, 126B, 124-127.
52. Fletcher, P.J. Psychopharmacol., 1988, 96, 237-242.
53. Montgomery, S.A. Neuropsychopharmacol., 2001, 11, S21.03
54. Hartfield, A.W., Moore, N.A., Clifton, P.G. Pharmacol. Biochem. & Behav., 2003, 76, 251-258.